Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Whether circulating tumor cells (CTCs) can be used as an indicator of treatment response in breast cancer (BC) needs to be clarified. We addressed this issue by a meta-analysis. PubMed, EMBase and Cochrane library databases were searched in June 2016. Effect measures were estimated as pooled risk ratio (RR), odds ratio (OR) or mean difference by fixed- or random-effect models, according to heterogeneity of included studies. In total, 50 studies with 6712 patients were recruited. Overall analysis showed that there was a significant reduction of CTC-positive rate (RR = 0.68, 95% CI: 0.61–0.76, P < 0.00001) after treatment. Subgroup analyses revealed that neoadjuvant treatment, adjuvant treatment, metastatic treatment or combination therapy could reduce the CTC-positive rate, but surgery could not; moreover, the reduction was only found in HER2+ or HER2- patients but not in the triple-negative ones. Reduction of CTC-positive rate was associated with lower probability of disease progression (OR = 0.54, 95% CI: 0.33–0.89, P = 0.01) and longer overall survival period (mean difference = 11.61 months, 95% CI: 8.63–14.59, P < 0.00001) as well as longer progression-free survival period (mean difference = 5.07 months, 95% CI: 2.70–7.44, P < 0.0001). These results demonstrate that CTC status can serve as an indicator to monitor the effectiveness of treatments and guide subsequent therapies in BC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therapeutic regimes including metastatic treatment, adjuvant treatment, neoadjuvant treatment, or combination therapy were equally effective in reducing CTC positivity and the chance of disease progression [151].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Another study, involving 6712 breast cancer patients showed a decrease in the number of CTCs only in human epidermal growth factor receptor 2 (HER2+) or HER2- patients but not in the triple-negative ones and nor in patients who underwent surgery.”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [151]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
Smerage, J. B., Barlow, W. E., Hortobagyi, G. N., Winer, E. P., Leyland-Jones, B., Srkalovic, G., Tejwani, S., Schott, A. F., O'Rourke, M. A., Lew, D. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2561 · Cited by 648
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
Rack, B., Schindlbeck, C., Jückstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T. W. P., Lorenz, R., Tesch, H., Fasching, P. A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju066 · Cited by 615
Müller, V., Stahmann, N., Riethdorf, S., Rau, T., Zabel, T., Goetz, A., Jänicke, F., & Pantel, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2469 · Cited by 403
Pierga, J.-Y., Bidard, F.-C., Mathiot, C., Brain, E., Delaloge, S., Giachetti, S., de Cremoux, P., Salmon, R., Vincent-Salomon, A., & Marty, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0030 · Cited by 369
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Janni, W. J., Rack, B., Terstappen, L. W. M. M., Pierga, J.-Y., Taran, F.-A., Fehm, T., Hall, C., de Groot, M. R., Bidard, F.-C., Friedl, T. W. P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1603 · Cited by 363
Ignatiadis, M., Lee, M., & Jeffrey, S. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1190 · Cited by 355
Xenidis, N., Ignatiadis, M., Apostolaki, S., Perraki, M., Kalbakis, K., Agelaki, S., Stathopoulos, E. N., Chlouverakis, G., Lianidou, E., Kakolyris, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0497 · Cited by 238
Liu, Z., Fusi, A., Klopocki, E., Schmittel, A., Tinhofer, I., Nonnenmacher, A., & Keilholz, U. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-70 · Cited by 189
Bidard, F., Mathiot, C., Degeorges, A., Étienne-Grimaldi, M.-C., Delva, R., Pivot, X. B., Veyret, C., Bergougnoux, L., de Crémoux, P., Milano, G. A., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq052 · Cited by 160
Cited by
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“Therapeutic regimes including metastatic treatment, adjuvant treatment, neoadjuvant treatment, or combination therapy were equally effective in reducing CTC positivity and the chance of disease progression [151].”
BackgroundLiquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology
Palmirotta, R., Lovero, D., Cafforio, P., Felici, C., Mannavola, F., Pellè, E., Quaresmini, D., Tucci, M., & Silvestris, F. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918794630 · Cited by 423
Clinical applications of the CellSearch platform in cancer patients
Riethdorf, S., O'Flaherty, L., Hille, C., & Pantel, K. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.01.011 · Cited by 275
Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples
Russano, M., Napolitano, A., Ribelli, G., Iuliani, M., Simonetti, S., Citarella, F., Pantano, F., Dell’Aquila, E., Anesi, C., Silvestris, N., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01601-2 · Cited by 260
Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring
Martins, I., Ribeiro, I. P., Jorge, J., Gonçalves, A. C., Sarmento-Ribeiro, A. B., Melo, J. B., & Carreira, I. M. (2021) · Genes · doi:10.3390/genes12030349 · Cited by 205
“Given that these cells are closely involved in the metastatic process, monitoring them might help predict the patients’ post-treatment outcomes and risk of metastasis [88,89].”
BackgroundBone Metastasis of Breast Cancer
Tahara, R. K., Brewer, T. M., Theriault, R. L., & Ueno, N. T. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-20301-6_7 · Cited by 169
Deciphering Tumour Heterogeneity: From Tissue to Liquid Biopsy
Gilson, P., Merlin, J., & Harlé, A. (2022) · Cancers · doi:10.3390/cancers14061384 · Cited by 157
Larsson, A.-M., Jansson, S., Bendahl, P., Jørgensen, C. L. T., Loman, N., Graffman, C., Lundgren, L., Aaltonen, K. E., & Rydén, L. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0976-0 · Cited by 121
“The usefulness of CTC count in prediction of treatment efficacy has been shown [16, 25, 26], and our results support the application of CTCs as a marker of therapy response in women with MBC receiving systemic therapy.”
BackgroundResultPlasma-Derived Extracellular Vesicle Phosphoproteomics through Chemical Affinity Purification
Iliuk, A. B., Wu, X., Li, L., Sun, J., Hadisurya, M., Boris, R. S., & Tao, W. A. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00151 · Cited by 97
The biology and clinical potential of circulating tumor cells
Ložar, T., Geršak, K., Čemažar, M., Kuhar, C. G., & Jesenko, T. (2019) · Radiology and Oncology · doi:10.2478/raon-2019-0024 · Cited by 97
Costa, C., Muinelo‐Romay, L., Cebey-López, V., Pereira‐Veiga, T., Martínez-Peña, I., Abreu, M., Abalo, A., Lago‐Lestón, R. M., Abuín, C., Palacios, P., et al. (2020) · Cancers · doi:10.3390/cancers12051111 · Cited by 71
“This result is also consistent with a recent meta-analysis showing that CTC status is a useful indicator to monitor the treatment response and to predict the outcome of patients with MBC [13].”
ResultNevel, K. S., DiStefano, N. M., Lin, X., Skakodub, A., Ogilvie, S. Q., Reiner, A. S., Pentsova, E. I., & Boire, A. A. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz208 · Cited by 67
Balakrishnan, A., Koppaka, D., Anand, A., Deb, B., Grenci, G., Viasnoff, V., Thompson, E. W., Gowda, H., Bhat, R., Rangarajan, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-44404-y · Cited by 63
Jin, L., Zhao, W., Zhang, J., Chen, W., Xie, T., Wang, L., Fan, W.-H., Xie, S., Shen, J., Zheng, H., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2825 · Cited by 63
Flores, B. C. T., Silva, V. S. E., Abdallah, E. A., de Mello, C. A. L., Silva, M. L. G., Mendes, G. G., Braun, A. C., Aguiar, S., & Chinen, L. T. D. (2019) · Cells · doi:10.3390/cells8070641 · Cited by 57
“Additionally, CTC kinetics can be used to monitor tumor response to systemic treatment [19,20].”
Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer
Chen, W., Zhang, J., Huang, L., Chen, L., Zhou, Y., Tang, D., Xie, Y., Wang, H., & Huang, C. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.10.009 · Cited by 51
Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer
Angeles, A. K., Janke, F., Bauer, S., Christopoulos, P., Riediger, A. L., & Sültmann, H. (2021) · Cancers · doi:10.3390/cancers13225615 · Cited by 47
Li, W., Zhou, L., Zheng, M., & Jin, F. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.07.008 · Cited by 44
“Yan et al.(5) included 50 studies with 6,712 BC patients in a meta-analysis and found that CTC counts significantly reduced after treatment, compared to pretreatment, and that the decreased CTC counts predicted an increased overall survival.”
BackgroundCollective metastasis: coordinating the multicellular voyage
Wrenn, E. D., Huang, Y. C., & Cheung, K. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10111-0 · Cited by 44
Short-Term Ex Vivo Culture of CTCs from Advance Breast Cancer Patients: Clinical Implications
Carmona-Ule, N., González-Conde, M., Abuín, C., Cueva, J. F., Palacios, P., López‐López, R., Costa, C., & Dávila-Ibáñez, A. B. (2021) · Cancers · doi:10.3390/cancers13112668 · Cited by 42
“High CTC numbers have been linked with worse outcome in prostate, colon and breast cancer metastatic patients [4–6] and the increase in number over time is an indicative of therapy failure [7].”
BackgroundSpiliotaki, M., Neophytou, C. M., Vogazianos, P., Stylianou, I., Gregoriou, G., Constantinou, A. I., Deltas, C. C., & Charalambous, H. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13317 · Cited by 43
The Prospect and Challenges to the Flow of Liquid Biopsy in Africa
Temilola, D. O., Wium, M., Coulidiati, T. H., Adeola, H. A., Carbone, G. M., Catapano, C. V., & Zerbini, L. F. (2019) · Cells · doi:10.3390/cells8080862 · Cited by 42
Ložar, T., Jesenko, T., Prevodnik, V. K., Čemažar, M., Hosta, V., Jeričević, A., Nolde, N., & Kuhar, C. G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554554 · Cited by 41
Smit, D. J., Pantel, K., & Jücker, M. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114589 · Cited by 41
Twomey, J. D., & Zhang, B. (2019) · Cancers · doi:10.3390/cancers11010094 · Cited by 37
Size-tuneable isolation of cancer cells using stretchable inertial microfluidics
Fallahi, H., Yadav, S., Phan, H., Ta, H. T., Zhang, J., & Nguyen, N. (2021) · Lab on a Chip · doi:10.1039/d1lc00082a · Cited by 34
Pharmacological ascorbate inhibits pancreatic cancer metastases via a peroxide-mediated mechanism
O’Leary, B. R., Alexander, M. S., Du, J., Moose, D. L., Henry, M. D., & Cullen, J. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-74806-2 · Cited by 37
Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review
Zdrenka, M., Kowalewski, A., Ahmadi, N., Sadiqi, R. U., Chmura, Ł., Borowczak, J., Maniewski, M., & Szylberg, Ł. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9265 · Cited by 34
“On the other hand, the absence of PD-L1-positive CTCs or a decreaseinthenumberofCTCspredictedabetterprognosisand a sustained response to long-term immunotherapy [135, 136].”
BackgroundThe Utility of Liquid Biopsy in Central Nervous System Malignancies
Nevel, K. S., Wilcox, J. A., Robell, L., & Umemura, Y. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0706-x · Cited by 30
Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing
Yu, J., Gemenetzis, G., Kinny‐Köster, B., Habib, J. R., Groot, V. P., Teinor, J. A., Yin, L., Pu, N., Hasanain, A., van Oosten, F., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.08.043 · Cited by 30
Fridrichová, I., Kalinkova, L., & Čierniková, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012141 · Cited by 32
Yekula, A., Muralidharan, K., Rosh, Z. S., Youngkin, A. E., Kang, K. M., Balaj, L., & Carter, B. S. (2020) · Advanced Biosystems · doi:10.1002/adbi.202000029 · Cited by 31
Pancreatic cancer circulating tumor cells: applications for personalized oncology
DiPardo, B. J., Winograd, P., Court, C. M., & Tomlinson, J. S. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1511429 · Cited by 28
Pizzutilo, E. G., Pedrani, M., Amatu, A., Ruggieri, L., Lauricella, C., Veronese, S. M., Signorelli, D., Cerea, G., Giannetta, L. G., Siena, S., et al. (2021) · Cancers · doi:10.3390/cancers13092265 · Cited by 26
“Such reduction was also documented in other cancer types [92].”
ResultVogl, T. J., Riegelbauer, L. J., Oppermann, E., Kostantin, M., Ackermann, H., Trzmiel, A., Stein, S., Eichler, K., Zharov, V. P., Roy, D., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246527 · Cited by 25
Clinical applications of circulating tumor cells in patients with solid tumors
Smit, D. J., Schneegans, S., & Pantel, K. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-024-10267-5 · Cited by 26
“For treatment monitoring, a meta-analysis also reported that in breast cancer patients CTC counts decrease after anti-tumor therapy and can therefore be used as an indicator of treatment response [52].”
Liquid biopsies in thyroid cancers: a systematic review and meta-analysis
Zeyghami, W., Hansen, M.-L. U., Jakobsen, K. K., Groenhøj, C., Feldt‐Rasmussen, U., von Buchwald, C., & Hahn, C. H. (2023) · Endocrine Related Cancer · doi:10.1530/erc-23-0002 · Cited by 24
Li, S., Yan, W., Yang, X., Chen, L., Fan, L., Liu, H., Liu, K., Zhang, Y., & Jiang, J. (2019) · BMC Cancer · doi:10.1186/s12885-019-6158-3 · Cited by 22
Self-citationMatsumura, H., Shen, L. T., Isozaki, A., Mikami, H., Yuan, D., Miura, T., Kondo, Y., Mori, T., Kusumoto, Y., Nishikawa, M., et al. (2023) · Lab on a Chip · doi:10.1039/d2lc00856d · Cited by 21
Does Primary Tumor Resection Induce Accelerated Metastasis in Breast Cancer? A Review
Jiao, Y., & Lv, Q. (2022) · Journal of Surgical Research · doi:10.1016/j.jss.2022.11.064 · Cited by 21
Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles
Wang, G., Benasutti, H., Jones, J. F., Shi, G., Benchimol, M. J., Pingle, S. C., Kesari, S., Yeh, Y., Hsieh, L.-E., Liu, Y., et al. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.10.060 · Cited by 19
Förnvik, D., Aaltonen, K. E., Chen, Y., George, A. M., Brueffer, C., Rigo, R., Loman, N., Saal, L. H., & Rydén, L. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05326-5 · Cited by 21
Gauging the Impact of Cancer Treatment Modalities on Circulating Tumor Cells (CTCs)
Mathias, T. J., Chang, K. T., Martin, S. S., & Vitolo, M. I. (2020) · Cancers · doi:10.3390/cancers12030743 · Cited by 18
Narbe, U., Bendahl, P., Aaltonen, K. E., Fernö, M., Forsare, C., Jørgensen, C. L. T., Larsson, A.-M., & Rydén, L. (2020) · Cells · doi:10.3390/cells9071718 · Cited by 18
Triantafillu, U. L., Park, S., & Kim, Y. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800112 · Cited by 18
Insights into brain metastasis: Recent advances in circulating tumor cell research
Klotz, R. V., & Yu, M. (2020) · Cancer Reports · doi:10.1002/cnr2.1239 · Cited by 21
Current Advances and Future Perspectives of Cerebrospinal Fluid Biopsy in Midline Brain Malignancies
Pan, Y., Long, W., & Liu, Q. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0689-3 · Cited by 16
O’Toole, S. A., Spillane, C. D., Huang, Y., Fitzgerald, M. C., Ffrench, B., Mohamed, B. M., Ward, M. P., Gallagher, M. F., Kelly, T. E., O’Brien, C. P., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05658-7 · Cited by 15
Mira, J. M., Sapre, A. A., Walker, B. S., Bueno, J., Gustafson, K. T., Tu, E. L., Fischer, J. M., Wong, M. H., Esener, S. C., & Chiu, Y. (2021) · Communications Biology · doi:10.1038/s42003-021-02651-8 · Cited by 16
Mittendorf, E. A., Bartlett, J. M. S., Lichtensztajn, D. Y., & Chandarlapaty, S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200981 · Cited by 15
Raj, R., Kumar, A., Sood, P., Kumar, R., & Rana, V. (2023) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.2.3.8 · Cited by 14
Khanna, S., Padhan, P., Das, S., Jaiswal, K. S., Tripathy, A., Smita, S., Tripathy, S. K., Raghav, S. K., & Gupta, B. (2018) · ChemistrySelect · doi:10.1002/slct.201802671 · Cited by 14
Rapanotti, M. C., Cugini, E., Campione, E., Raimondo, C. D., Costanza, G., Rossi, P., Ferlosio, A., Bernardini, S., Orlandi, A., Luca, A. D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411792 · Cited by 15
Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities
Banys‐Paluchowski, M., Reinhardt, F., & Fehm, T. N. (2020) · Applied Sciences · doi:10.3390/app10093311 · Cited by 12
“In most breast cancer patients, CTC numbers declined rapidly under systemic therapies compared to those before therapy started [8].”
BackgroundRamirez, J. G., Smit, D. J., Viol, F., Schrader, J., Ghadban, T., Pantel, K., Izbicki, J. R., & Reeh, M. (2021) · Cancers · doi:10.3390/cancers13194980 · Cited by 12
“CTC and DTC detection in cancer patients is a major topic in today’s cancer research and provides a rationale for risk stratification [20–22], treatment monitoring [23] and novel treatment strategies for personalized medicine [24–27].”
BackgroundLiu, M., Janni, W., Georgoulias, V., Yardley, D. A., Harbeck, N., Wei, X., McGovern, D. M. T., & Beck, R. M. (2019) · Cancer Management and Research · doi:10.2147/cmar.s208712 · Cited by 12
Zhang, Y., Zhang, Z., Zheng, D., Huang, T., Fu, Q., & Liu, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043338 · Cited by 11
Wang, J., Gao, Z., Dong, M., Li, J., Jiang, H., Xu, J., Gu, J., & Wang, D. (2023) · Microchimica Acta · doi:10.1007/s00604-023-05797-w · Cited by 11
Lopresti, A., Boudin, L., Finetti, P., Garnier, S., Aulas, A., Liberatoscioli, M. L., Cabaud, O., Guillé, A., de Nonneville, A. T., Costa, Q. D., et al. (2022) · Cancers · doi:10.3390/cancers14040932 · Cited by 11
Lisencu, L. A., Trancă, S., Bonci, E.-A., Paşca, A., Mihu, C., Irimie, A., Tudoran, O. M., Bălăcescu, O., & Lisencu, I. C. (2022) · Biomedicines · doi:10.3390/biomedicines10040769 · Cited by 10
“[47] found that a CTC positive rate decreased after systemic treatment, except for the triple-negative subtype, emphasizing the necessity of finding new management strategies for this subtype.”
BackgroundMethodNingsi, R., Elazezy, M., Stegat, L., Laakmann, E., Peine, S., Riethdorf, S., Müller, V., Pantel, K., & Joosse, S. A. (2022) · Cancers · doi:10.3390/cancers14112621 · Cited by 10
“[22], showing the relevance of monitoring treatment efficacy.”
BackgroundResultPortella, L., Bertolini, G., Guardascione, G., Febbraro, D. G. D., Ieranò, C., D’Alterio, C., Rea, G., Napolitano, M., Santagata, S., Trotta, A. M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35524 · Cited by 9
“A meta-analysis including 50 studies with 6712 breast cancer patients showed that CTCs decrease after therapy [15].”
MethodA glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers
Alshahrani, M. M. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2022.01.017 · Cited by 10
Twomey, J. D., & Zhang, B. (2023) · Biomedicines · doi:10.3390/biomedicines11030934 · Cited by 10
“Measuring CTCs in a patient’s blood has become a non-invasive way to check whether they are at a high risk of developing metastatic cancers [2,3] or to monitor their response to treatment [4,5].”
BackgroundBraun, M., Markiewicz, A., Kordek, R., Sądej, R., & Romańska, H. (2019) · Cancers · doi:10.3390/cancers11020143 · Cited by 10
“, who included 6712 IBC patients from 50 studies and showed a strong predictive value of CTCs status during the treatment for both PFS and OS [80].”
BackgroundMansouri, S., Mokhtari-Hesari, P., Naghavi-Al-Hosseini, F., Majidzadeh‐A, K., & Farahmand, L. (2019) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x14666190306103759 · Cited by 9
Chiang, C., Kao, Y.-C., Webster, T. J., Shyu, W., Cheng, H., Liu, T.-Y., & Chen, S. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00501k · Cited by 9
Manso, L., Antón, F. M., Perón, Y. I., Mingorance, J. I. D., García, P. B., Gonzalez, M. J. E., Martínez-Jáñez, N., López-González, A., Olier, C., García, A. B., et al. (2019) · The Breast Journal · doi:10.1111/tbj.13199 · Cited by 9
“A meta‐analysis investigating the CTC‐reducing effects of different treatments in breast cancer showed that CTCs are reduced after neoadjuvant, adjuvant and metastatic treatment, as well as combination therapy, but not after surgery, and that CTC‐reduced patients had longer OS and PFS as compared to CTC‐unchanged or ‐…”
BackgroundResultWu, Q., Zhu, L., Wei, X., Zhang, M., Zhang, C., You, Z., Zhang, S., Song, Y., Liu, D., & Yang, C. J. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.133274 · Cited by 9
Jin, D., Qian, L., Xia, J., Zhang, R., Yang, G., Zhang, L., Xue, W., Cao, M., Dong, L., & Chen, H. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00785-x · Cited by 9
The Role of Circulating Tumor Cells in Chemoresistant Metastatic Breast Cancer
Lisencu, L. A., Bonci, E.-A., Irimie, A., Bălăcescu, O., & Lisencu, C. I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040684 · Cited by 8
“[33] addressed this topic in a meta-analysis that included 50 studies and 6712 patients; they reported the CTC positivity rate decreased after therapy, suggesting CTCs could be helpful in monitoring treatment response in breast cancer patients.”
Exosomes: Key tools for cancer liquid biopsy
Panfoli, I., Bruschi, M., & Candiano, G. (2022) · Biocell · doi:10.32604/biocell.2022.020154 · Cited by 8
Clinical Relevance and Therapeutic Application of CTCs in Advanced Breast Cancer
Bañuelos, J., López, C. R., Cortegoso, A., Ozores, P. P., & Garcia, T. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-35805-1_10 · Cited by 9
Circulating tumor cells and the metastatic process: the complexity of malignancy
Raimo, T. D., Santis, E. D., Coppola, L., D'Andrea, M. R., & Angelini, F. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.50 · Cited by 8
“overall-survival, to date no consensus has been established regarding biological markers to be used to identify these cells([61-63]).”
BackgroundGao, Y., Fan, W.-H., Duan, C., Zhao, W., Zhang, J., & Kang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.643003 · Cited by 7
Clinical Biomarkers for Early Identification of Patients with Intracranial Metastatic Disease
Gaebe, K., Li, A. Y., & Das, S. (2021) · Cancers · doi:10.3390/cancers13235973 · Cited by 7
Mihalcioiu, C. L. D., Li, J., Badescu, D., Camirand, A., Kremer, N., Bertos, N., Ömeroğlu, A., Sébag, M., Battista, J. A. D., Park, M., et al. (2023) · PubMed Central · Cited by 6
Lai, H.-C., Huang, H.-H., Hao, Y.-J., Lee, H.-L., Wang, C.-C., Ling, T., Wu, J., & Tseng, F. (2024) · Current Oncology · doi:10.3390/curroncol31090421 · Cited by 6
“The CTM and subtypes of CTM with specific components might be valuable tools and promising biomarkers to be used to investigate the biogenesis of CTC/CTM and the potential mechanism of cancer metastasis extensively, and to be further applied to monitor the condition of disease in individual cancer…”
MethodCirculating Tumor Cells Culture: Methods, Challenges, and Clinical Applications
Zhou, Z., Cai, S., Zhou, X., Zhao, W., Sun, J., Zhou, Z., Yang, Z., Li, W., Wang, Z., Zou, H., et al. (2024) · Small Methods · doi:10.1002/smtd.202401026 · Cited by 6
Peixoto, A., Cotton, S., Santos, L. L., & Ferreira, J. A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73119-9_1 · Cited by 6
Jou, H., Ho, H.-C., Huang, K.-Y., Chen, C., Chen, S.-W., Lo, P.-H., Huang, P., Huang, C.-E., & Chen, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315139 · Cited by 7
Jin, L., Fan, W.-H., Luan, Y., Wu, M., & Zhao, W. (2021) · PeerJ · doi:10.7717/peerj.11366 · Cited by 6
“diagnostic tool for screening and early diagnosis of BC and as a surveillance tool for real-time monitoring of disease progression and patients response to treatment (Jin et al., 2020; Yan et al., 2017).”
MethodGoodman, C. R., & Speers, C. W. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.08.039 · Cited by 7
Chang, K. T., Thompson, K. N., Pratt, S. J. P., Ju, J. A., Lee, R., Mathias, T. J., Mull, M. L., Annis, D. A., Ory, E. C., Stemberger, M. B., et al. (2023) · Cancers · doi:10.3390/cancers15030884 · Cited by 5
Nikanjam, M., & Kurzrock, R. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.10.004 · Cited by 4
Zhang, Q., Fang, Y., She, C., Zheng, R., Hong, C., Chen, C., & Wu, J. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11553 · Cited by 4
Expression of circulating tumour cells in oral squamous cell carcinoma: An ex vivo pilot study
Sahana, N. S., Yadava, S. T., Choudhary, B., Ravindran, F., Khatoon, H., & Kulkarni, M. (2023) · Journal of Oral and Maxillofacial Pathology · doi:10.4103/jomfp.jomfp_131_23 · Cited by 4
Neoadjuvant therapy and translational biomarkers for metastatic risk in early breast cancer
McCracken, A., Grafinger, O. R., Leong, H. S., Lohmann, A. E., Jerzak, K. J., & Das, S. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103111 · Cited by 5
Circulating Tumor Cells and Cell-free Tumor DNA in Evaluation and Management of Gliomas
Nevel, K. S. (2022) · Advances in Oncology · doi:10.1016/j.yao.2022.01.006 · Cited by 3
Merkley, S. D., Kang, H., Brown-Glaberman, U. A., & Marchetti, D. (2025) · Cancers · doi:10.3390/cancers17162717 · Cited by 2
“Accordingly, while the treatment regimens applied to patients in our datasets may affect CTC presence and clustering, each regimen has the potential to increase or decrease CTC counts in ways peculiar to each individual’s unique history [58–61].”
The Role of Circulating Tumor Cells in Chemoresistant Metastatic Breast Cancer
Alexandra, L., Cosmin, L., Eduard-Alexandru, L., Alexandru, B., & Balacescu, I. O. (2021) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pamed2ed.3.2021.13 · Cited by 2
Bohaumilitzky, L., Gebert, J. F., Doeberitz, M. V. K., Kloor, M., & Ahadova, A. (2023) · Medizinische Genetik · doi:10.1515/medgen-2023-2049 · Cited by 4
Alex, T. S., Lang, D. K., Zakir, F., Mirza, A., & Iqbal, Z. (2022) · Environmental chemistry for a sustainable world · doi:10.1007/978-3-031-14848-4_1 · Cited by 1
Applications of biomarkers for different purposes in drug development
Halim, A. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816121-0.00002-7 · Cited by 1
McCartney, A., Benelli, M., & Leo, A. D. (2019) · The Breast · doi:10.1016/s0960-9776(19)31130-0 · Cited by 1
Bone Marrow Micrometastases and Circulating Tumor Cells
Kılıçkap, S., Aktaş, B. Y., & Ozisik, Y. Y. (2019) · Springer eBooks · doi:10.1007/978-3-030-04606-4_13 · Cited by 1
Ghosh, A., & Chaudhuri, S. (2024) · Biomedicine · doi:10.51248/.v44i1.4045 · Cited by 1
“CTCs may have the potential to be counted as the dynamic diagnostic tool as they increase or decrease with the increase or decrease of tumour burden which is already documented for breast cancer and pancreatic cancer (16, 17).”
BackgroundMetastatic Disease in the Central Nervous System
Wilcox, J. A., & Boire, A. A. (2023) · doi:10.1093/med/9780197573778.003.0012 · Cited by 1
Bone Marrow Micrometastases and Circulating Tumor Cells
Kılıçkap, S., Altundag, M. K., & Ozisik, Y. Y. (2015) · Springer eBooks · doi:10.1007/978-3-319-22843-3_12
Circulating Cell-Free DNA and Cancer Therapy Monitoring: Methods and Potential
Gahan, P. B. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8973-7_3
Metadata
- Authors
- Yan, W.-T., Cui, X., Chen, Q., Li, Y.-F., Cui, Y.-H., Wang, Y., & Jiang, J.
- Affiliations
- Army Medical University (CN)
- Corresponding author
- Jiang, Jun
- Venue
- Scientific Reports
- Published
- 2017-03-24
- Volume
- 7
- Issue
- 1
- Pages
- 43464-43464
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5364512
- OpenAlex
- W2599986806
- Cited by
- 113
- References
- 64
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2023: 16 · 2022: 14 · 2021: 20 · 2020: 20 · 2019: 19 · 2018: 12 · 2017: 1
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- circulating tumor cells, breast cancer, treatment response monitoring, neoadjuvant therapy, adjuvant therapy, metastatic breast cancer, HER2-positive breast cancer, triple-negative breast cancer, disease progression, overall survival, progression-free survival
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Monitoring, Physiologic, Neoplastic Cells, Circulating, Prognosis, Risk Factors, Biomarkers, Tumor, Gene Expression, Odds Ratio, Survival Analysis, Disease Progression, Erb-b2 Receptor Tyrosine Kinases, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.